A5026541269- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Systemic Lupus Erythematosus Research
- Ocular Diseases and Behçet’s Syndrome
- Myasthenia Gravis and Thymoma
- Retinal and Optic Conditions
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Hereditary Neurological Disorders
- Long-Term Effects of COVID-19
- CNS Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Rheumatoid Arthritis Research and Therapies
- Multiple Myeloma Research and Treatments
- Parkinson's Disease and Spinal Disorders
- Antifungal resistance and susceptibility
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Cerebral Venous Sinus Thrombosis
- Cannabis and Cannabinoid Research
- Cerebrospinal fluid and hydrocephalus
- Autoimmune Neurological Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Spinal Hematomas and Complications
Rabin Medical Center
2016-2025
Massachusetts General Hospital
2021-2025
Tel Aviv University
2015-2024
Harvard University
2021-2024
Charité - Universitätsmedizin Berlin
2024
Humboldt-Universität zu Berlin
2024
Freie Universität Berlin
2024
Max Delbrück Center
2024
Foundation Fighting Blindness
2023
Multiple Sclerosis Center Of Northeastern New York
2020-2022
Objective The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. aim the present open-label observational study was to assess effect on motor and non–motor symptoms PD. Methods Twenty-two PD attending disorder clinic tertiary center 2011 2012 were evaluated at baseline 30 minutes after smoking using following battery: Unified Disease Rating Scale,...
To investigate whether visual disability which is known to accumulate by poor recovery from optic neuritis (ON) attacks can be lessened early treatment, we investigated the time symptom onset high-dose IV methylprednisolone (IVMP) affected recovery.A retrospective study was performed in a consecutive cohort of patients following their first aquaporin-4 (AQP4)-IgG or myelin oligodendrocyte glycoprotein (MOG)-IgG-ON. Best-corrected acuity (BCVA) ON eyes at 3 months (BCVA3mo) correlated with...
Recent studies suggest that maintenance intravenous immunoglobulin (IVIG) may be an effective treatment to prevent relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); however, most of these had pediatric cohorts, and few have evaluated IVIG adult patients.To determine the association with prevention relapse a large cohort patients MOGAD.This was retrospective study conducted from January 1, 2010, October 31, 2021. Patients were recruited 14 hospitals 9...
Abstract Background and purpose Although the COVID‐19 vaccines are currently recommended for people with multiple sclerosis (MS), fact that they were not specifically tested in MS raises uncertainty regarding their safety this population. The of study was to report real‐life data BNT162b2 vaccine a cohort patients. Methods An anonymous survey distributed 425 Participants asked general demographic disease‐related questions specific profile vaccine. Results Of patients, 262 completed...
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can cause optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis (ADEM). Immunotherapy is often used for relapsing disease, but there variability in treatment decisions. Objective: The objective was to determine the annualized relapse rates (ARRs) and incidence rate ratios (IRRs) compared pre-treatment relapse-freedom probabilities among patients receiving steroids, B-cell depletion...
Background Optic neuritis (ON) in patients with anti-myelin oligodendrocyte glycoprotein (MOG)-IgG antibodies has been associated a better clinical outcome than anti-aquaporin 4 (AQP4)- IgG ON. Average retinal nerve fiber layer thickness (RNFL) correlates visual after Objectives The aim of this study was to examine whether anti-MOG-IgG ON is average RNFL compared anti-AQP4-IgG ON, and corresponds outcome. Methods A retrospective done consecutive cohort following generalized estimating...
Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment high-dose corticosteroids for ON is based on a North American study population, which did not address timing or antibody serostatus. Acute Neuritis Network (ACON) presents global, prospective, observational protocol primarily designed to investigate effect...
Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, neurodegenerative disorder, characterized by the degeneration of motor neurons. Oxidative stress plays central role in disease progression, concert with an enhanced glutamate excitotoxicity and neuroinflammation. DJ-1 mutations, leading to loss functional protein, cause familial Parkinson's neuron several patients. responds oxidative important cellular defense mechanisms. We aimed investigate whether alters course severity ALS...
Background: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown. Objective: objective was to describe the outcomes IVIG treatment MOGAD attacks. Methods: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients’ demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before attack, at nadir attack...
Abstract Proinflammatory cytokines, such as (IL: interleukin) IL-6 and IL-17A, complement fixation are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD). Blocking receptor or C5 pathway reduces relapse risk. However, role interleukin (IL)-6 aquaporin-4 (AQP4) autoimmunity remains unclear. To investigate anti-AQP4 immunoglobulin (AQP4-IgG)/AQP4 immunocomplex on induction profile ex vivo cytokine surface marker expression peripheral blood mononuclear cells...